NCT05442957 (BRIGHT) is a NA clinical trial of BRIGHT in Head and Neck Cancer, sponsored by Medical University of South Carolina.

Who is sponsoring NCT05442957?

NCT05442957 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT05442957?

Interventions in NCT05442957: BRIGHT, Attention Control.

What condition does NCT05442957 study?

NCT05442957 studies Head and Neck Cancer, Body Image Disturbance, Body Image, Survivorship, Psychosocial Impairment, Mental Health Issue.

Is NCT05442957 still recruiting?

NCT05442957 is currently recruiting now. Last updated 24 September 2025.

Last reviewed 2025-09-24 · How we verify

NCT05442957: BRIGHT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT

Recruiting now NA Last updated 24 September 2025

What this trial tests

NA trial testing BRIGHT in Head and Neck Cancer in 180 participants. Currently enrolling.

Timeline

14 February 2023

Primary endpoint
30 January 2027

30 March 2027

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	supportive care
Enrollment	180
Start date	14 February 2023
Primary completion	30 January 2027
Estimated completion	30 March 2027
Sites	5 locations across United States

Drugs / interventions tested

BRIGHT
Attention Control

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →
Body Image Disturbance — all drugs for Body Image Disturbance →
Body Image — all drugs for Body Image →
Survivorship — all drugs for Survivorship →

Sponsor

Medical University of South Carolina

Who can join

18 and older, any sex, with Head and Neck Cancer or Body Image Disturbance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this multi-center randomized clinical trial, head and neck cancer (HNC) survivors with clinically significant body image distress (BID) (N=180) will be randomized to BRIGHT (a brief video tele-cognitive behavioral therapy intervention) or Attention Control (AC, a manualized tele-supportive care intervention that controls for professional attention, dose, delivery method, and common factors). HNC survivors will complete IMAGE-HN (a validated patient-reported outcome measure \[PROM\] of HNC-related body image distress \[BID\]; primary endpoint), measures of psychological and social well-being and quality of life (QOL), and measures of theory-derived mechanisms of change underlying BRIGHT (mediators).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Protocol for a multisite, parallel-group, randomized clinical trial comparing a brief tele-cognitive behavioral therapy intervention (BRIGHT) with attention control for the reduction of body image-related distress among head and neck cancer survivors.
Graboyes EM, Maurer SN, Kistner-Griffin E, Armeson K, et al · · 2025 · PMID 40139457 · DOI 10.1016/j.cct.2025.107888

Verify or expand the search:

Other trials of BRIGHT

Trials testing the same drug.

NCT03831100 — Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) 2.0 · NA · completed
NCT03866694 — Growing Together: Women in Opioid Treatment and Their Infants · NA · unknown

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05442957 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 24 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05442957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing